

Resource Summary Report

Generated by RRID on Aug 15, 2026

Alex's Lemonade Stand Foundation for Childhood Cancer Childhood Cancer Repository

RRID:SCR_025812

Type: Tool

Proper Citation

Alex's Lemonade Stand Foundation for Childhood Cancer Childhood Cancer Repository
(RRID:SCR_025812)

Resource Information

URL: <https://cccells.org/>

Proper Citation: Alex's Lemonade Stand Foundation for Childhood Cancer Childhood Cancer Repository (RRID:SCR_025812)

Description: Repository stores tissue samples and uses them to create cell lines. The cell lines and xenografts can be used as model to understand cancers and to test new treatments. Researchers all over the world can request cell lines and models to use in their research.

Synonyms: Childhood Cancer Repository

Resource Type: topical portal, biomaterial supply resource, portal, data or information resource, cell repository, disease-related portal, material resource

Keywords: Childhood cancer, tissue samples, create cell lines, xenografts,

Related Condition: Childhood Cancer

Funding: Cancer Prevention & Research Institute of Texas ;
Alexs Lemonade Stand Foundation

Resource Name: Alex's Lemonade Stand Foundation for Childhood Cancer Childhood Cancer Repository

Resource ID: SCR_025812

Alternate URLs: <https://www.alexслеmonade.org/childhood-cancer/for-families/repository>

Record Creation Time: 20241001T053245+0000

Record Last Update: 20260815T042944+0000

Ratings and Alerts

No rating or validation information has been found for Alex's Lemonade Stand Foundation for Childhood Cancer Childhood Cancer Repository.

No alerts have been found for Alex's Lemonade Stand Foundation for Childhood Cancer Childhood Cancer Repository.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zabala-Letona A, et al. (2026) Polyamine-dependent metabolic shielding regulates alternative splicing. *Nature*, 651(8106), 819.

Daley JD, et al. (2025) TGF β Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma. *Cancer research communications*, 5(8), 1441.

Cherkaoui S, et al. (2025) Reprogramming neuroblastoma by diet-enhanced polyamine depletion. *Nature*, 646(8085), 707.

Koomoa DT, et al. (2025) Novel Compounds Target Aberrant Calcium Signaling in the Treatment of Relapsed High-Risk Neuroblastoma. *International journal of molecular sciences*, 26(7).

Chugh S, et al. (2025) Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma. *Neoplasia (New York, N.Y.)*, 60, 100964.

Cidre-Aranaz F, et al. (2025) High Tau expression correlates with reduced invasion and prolonged survival in Ewing sarcoma. *Cell death discovery*, 11(1), 216.

Sanni A, et al. (2024) An Optimized Liquid Chromatography-Mass Spectrometry Method for Ganglioside Analysis in Cell Lines. *Cells*, 13(19).

Karki A, et al. (2022) Plexin-B2 and Semaphorins Do Not Drive Rhabdomyosarcoma Proliferation or Migration. *Sarcoma*, 2022, 9646909.

Pathania AS, et al. (2022) miR-15a and miR-15b modulate natural killer and CD8⁺T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma. *Molecular therapy oncolytics*, 25, 308.